Ixico enters deal with NUY Langone Health for drug trial
16th Oct 2020 16:23
(Sharecast News) - Data analytics company Ixico has entered into an agreement with NYU Langone Health to support a trial to determine if the immunosuppressant drug Sirolimus, approved by the FDA to prevent organ transplant rejection and for the treatment of a rare and progressive lung disease called lymphangioleiomyomatosis, is also able to slow the progression of disease in people with multiple system atrophy (MSA).
Read moreIxico joins Friedreich's Ataxia research consortium
24th Sep 2020 16:30
(Sharecast News) - Data analytics company Ixico has entered into a five-year collaboration with the Friedreich's Ataxia Research Alliance (FARA), it announced on Thursday, which it described as a non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's Ataxia (FA).
Read moreIxico joins Friedreich's Ataxia research consortium
24th Sep 2020 16:30
(Sharecast News) - Data analytics company Ixico has entered into a five-year collaboration with the Friedreich's Ataxia Research Alliance (FARA), it announced on Thursday, which it described as a non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's Ataxia (FA).
Read moreIxico selected to support Alzheimer's trial
21st Sep 2020 13:35
(Sharecast News) - Data analytics company Ixico has been selected by the Global Alzheimer's Platform Foundation (GAP) to support its planned 'Bio-Hermes' trial.
Read moreIxico FY revenues, underlying earnings ahead of forecasts
24th Aug 2020 09:18
(Sharecast News) - Data analytics company Ixico said on Monday that it had recorded "stronger-than-anticipated" second-half revenues and underlying earnings despite Covid-19.
Read moreIxico sees only 'modest' impact on trading from Covid-19
24th Jun 2020 09:41
(Sharecast News) - Data analytics company Ixico said on Wednesday that Covid-19 had only had a "modest" impact on trading and stated it expects to maintain double-digit revenue growth in 2021.
Read moreIxico in 'robust' position to handle short-term Covid-19 headwinds
20th Apr 2020 08:50
(Sharecast News) - Data analytics firm Ixico said on Monday that it was in a "robust" position to handle short-term headwinds stemming from the Covid-19 pandemic and associated government measures.
Read moreIxico inks ?10.5m contract, trading impacted by Covid-19 in 'multiple ways'
14th Apr 2020 09:32
(Sharecast News) - Neuroscience data analytics firm Ixico has inked a £10.5m contract for a late-phase open-label study into Huntington's disease, but warned that the Covid-19 pandemic had affected it in "multiple ways".
Read moreIxico joins Alzheimer's disease research initiative
3rd Feb 2020 14:05
(Sharecast News) - Artificial intelligence data analytics company Ixico announced funding support for the Alzheimer's Disease Neuroimaging Initiative (ADNI) on Monday, with two of its scientists to join the ADNI-Private Partner Scientific Board (PPSB).
Read moreDirector dealings: Ixico CEO ups stake
23rd Jan 2020 16:10
(Sharecast News) - Ixico revealed on Thursday that chief executive Giulio Cerroni had purchased 24,800 ordinary shares in the British clinical research firm.
Read moreIxico announces extensions to two studies
23rd Dec 2019 15:04
(Sharecast News) - Data analytics company Ixico announced a £1.8m extension to a phase 3 study in Huntington's Disease on Monday, which it had previously announced in September 2018.
Read moreIxico secures three new contracts, appoints chief business officer
28th Oct 2019 13:15
(Sharecast News) - AI data analytics company Ixico said on Monday that it had secured three new contracts and appointed a chief business officer.
Read moreIxico flags better-than-expected performance for full-year
15th Oct 2019 15:33
(Sharecast News) - Artificial intelligence data analytics company Ixico updated the market on its trading for the year ended 30 September on Tuesday, saying it expected its first full year of positive EBITDA since listing.
Read moreIXICO sees full-year results 'materially ahead' of market expectations
19th Aug 2019 09:55
(Sharecast News) - AIM-listed clinical research firm IXICO said on Monday that its annual results will be "materially ahead" of current market expectations following strong revenue growth in the second half.
Read moreIxico revenues on track to meet full-year market expectations
25th Apr 2019 08:35
(Sharecast News) - Data analytics firm Ixico expects half-year revenues to be in line with market expectations.
Read more